ResMed
938 hedge funds and large institutions have $22.2B invested in ResMed in 2026 Q1 according to their latest regulatory filings, with 105 funds opening new positions, 360 increasing their positions, 319 reducing their positions, and 97 closing their positions.
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
13% more repeat investments, than reductions
Existing positions increased: 360 | Existing positions reduced: 319
8% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 97
0.53% more ownership
Funds ownership: 66.49% → 67.02% (+0.53%)
1% less funds holding
Funds holding: 945 → 938 (-7)
5% less capital invested
Capital invested by funds: $23.4B → $22.2B (-$1.16B)
71% less call options, than puts
Call options by funds: $58.1M | Put options by funds: $201M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Amundi
Paris,
France
|
+$146M |
| 2 |
DAM
Diamant Asset Management
Ridgefield,
Connecticut
|
+$100M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$95M |
| 4 |
Two Sigma Investments
New York
|
+$77.9M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$77.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$74.2M |
| 2 |
Renaissance Technologies
New York
|
-$73.3M |
| 3 |
BlackRock
New York
|
-$63.5M |
| 4 |
Morgan Stanley
New York
|
-$51.1M |
| 5 |
KBC Group
Brussels,
Belgium
|
-$49.8M |
RMD Hedge Fund Activity: Q1 2026 in Review
938 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q1 2026, worth a combined $22.2B — down 5% from $23.4B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new RMD positions and 97 closed out — a net gain of 8 holders — while 360 added to existing stakes and 319 trimmed.
The largest buyer was Amundi, adding an estimated $146M. The largest seller was T. Rowe Price Associates, cutting an estimated $74.2M.
- 938 institutional investors held ResMed (RMD) as of Q1 2026, down from 945 in Q4 2025.
- Funds reported $22.2B of ResMed stock for Q1 2026, down 5% quarter-over-quarter.
- 105 funds opened new ResMed positions in Q1 2026 and 97 closed out, a net change of +8 holders.
- The largest ResMed buyer in Q1 2026 was Amundi, an estimated $146M added.
- The largest ResMed seller in Q1 2026 was T. Rowe Price Associates, an estimated $74.2M sold.
Based on aggregated 13F filings for Q1 2026.